Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
15:30-15:42 | 15:30-15:42 |
24-week combination treatment of TLR7 agonist TQ-A3334 and PD-L1 inhibitor TQ-B2450 enhanced HBsAg reduction in NAs-suppressed CHB patients: a preliminary analysis of a phase II study (OCEANcure05) |
Ting Wu | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
15:42-15:54 | 15:42-15:54 |
Immunogenicity of Inactivated COVID-19 Vaccines in Chronic Hepatitis B Patients with Antiviral Therapy |
Wenxin WANG | Peking University 302 Clinical Medical School |
15:54-16:06 | 15:54-16:06 |
Lipid nanoparticle-mediated delivery of mRNA vaccine for IL-21 achieves clearance of hepatitis B virus (HBV) persistence in mouse models |
Shenyan ZHANG | Huashan hospital |
16:06-16:18 | 16:06-16:18 |
Subcutaneous PD-L1 Antibody ASC22 (Envafolimab) plus Nucleos(t)ide Analogs Achieved Functional Cure of Chronic Hepatitis B in 42.9% of Patients with HBsAg ≤100 IU/mL: Interim Results from a Phase IIb Clinical Trial |
Jiandan QIAN | Peking university first hospital |
16:18-16:30 | 16:18-16:30 |
Clinical evaluation of metagenomic next-generation sequencing method for the diagnosis of suspected ascitic infection in patients with liver cirrhosis in a clinical laboratory |
Haoxin WU | Capital medical university. Beijing youan hospital |
16:30-16:42 | 16:30-16:42 |
Metabolic Factors and Steatosis Increase the Risk of Adverse Outcomes in Treatment-Naïve Chronic Hepatitis B Patients with Normal Alanine Aminotransferase |
Yuting DIAO | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
16:42-16:54 | 16:42-16:54 |
High rates of HBV functional cure among HIV/HBV coinfected Chinese adults on antiretroviral therapy |
Huan XIA | Tianjin Second People's Hospital |